All
FDA Grants Priority Review to Frontline Keytruda to Treat Recurrent, Metastatic HNSCC
February 11th 2019The Food and Drug Administration granted a priority review to the supplemental biologics license application for Keytruda (pembrolizumab) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Cholangiocarcinoma Foundation Aims to Increase Tumor Profiling and Clinical Trial Participation
February 8th 2019The Cholangiocarcinoma Foundation has won a grant from Bayer to create a website and outreach to patients and doctors to let them know that all patients with the disease need to have their tumors sequenced, because there are existing medicines and clinical trials that may help patients with actionable mutations more than the standard of care.
Trying Out A(nother) Breast Form after a Mastectomy
February 7th 2019I am the first to admit that I have a love-hate relationship with breast forms post-mastectomy. Every now and then, I do put one on. It comforts me to know that there are multiple options (especially for women who wear them regularly).
Erleada Improves Survival in Prostate Cancer Subset
February 1st 2019In topline findings from the phase 3 TITAN trial (NCT02489318) announced today by Janssen, Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) versus placebo in patients with metastatic castration-sensitive prostate cancer.